Myasthenia Gravis Market - Global Industry Analysis

Myasthenia Gravis Market

Global Myasthenia Gravis Market: By Drug Type, Size, Industry Share, Trends, Growth, Segments, Analysis and Forecast 2018–2025

Category: Healthcare Report Format : PDF Pages: 110 Report Code: ZMR-3927 Published Date: Mar-2019 Status : Published

Table Of Content


Free Analysis

Myasthenia Gravis is an autoimmune neuromuscular disorder that leads to serious muscle weakness. It is caused due to an error in the transmission of nerve impulses to muscles. It generally occurs when the normal communication between nerve and muscle disrupts at the neuromuscular joints. In this disorder, the antibodies present in the body destroy the receptor for acetylcholine at the neuromuscular joint, which, in turn, prevents the muscles from contracting and performing normal functions. There is no permanent cure for this condition and it affects one’s quality of life. The treatment helps in the improvement of the quality of life and life expectancy remains normal. The skeletal muscle weakness leads to the drooping eyelids, double vision, trouble in talking, walking trouble, etc. It mostly affects the eyes and facial muscles along with the gastrointestinal tract. The enlargement of the thymus or the development of thymoma can also be observed in myasthenia gravis patients. It can be diagnosed with the help of a blood test, nerve conduction test, and edrophonium test. Its treatment option includes the removal of thymus gland and medications, such as acetylcholinesterase inhibitors, immunosuppressant, etc.

As per the Myasthenia Gravis Foundation of America 2015, there were around 14 to 20 myasthenia gravis cases per 100,000 people, approximating nearly 36,000 to 60,000 cases of myasthenia gravis in the U.S. Furthermore, an increase in the number of autoimmune disorders coupled with strong product pipeline is also expected to drive the growth of the global myasthenia gravis market over the estimated period. The increase in healthcare expenditure, robust healthcare infrastructure, and growth in the awareness about the ailment among people is also anticipated to drive the growth of the global myasthenia gravis market. Moreover, increased adoption of novel therapies along with favorable reimbursement policies in developed economies will promote the myasthenia gravis market globally. Increased research and development activities and massive investments are expected to create new growth opportunities in the myasthenia gravis market. However, the high treatment costs, limited availability of FDA-approved drugs may inhibit the growth of the myasthenia gravis market in the future.

Global Myasthenia Gravis Market

The global myasthenia gravis market is segmented on the basis of treatment, diagnosis, and end-user. By diagnosis, the market is segmented into edrophonium tests, blood tests, pulmonary function tests, electrodiagnostic, imaging, and others. Blood tests are expected to hold the major market share. By treatment, the market is segmented into surgery, medication, plasmapheresis and intravenous immunoglobulin, autologous hematopoietic stem cell transplantation (HSCT), and others. The medication segment is expected to contribute majorly toward the global market over the forecast timespan. By end-user, the market is segmented into hospitals, academic research institutes, clinics, and others. Hospitals are expected to hold the major market share in the future.

North America is expected to lead the global myasthenia gravis market over the forecast time period due to the increased adoption of novel therapies, increase in awareness among the people, favorable reimbursement policies, the presence of developed countries, such as the U.S. and Canada, and robust healthcare infrastructure. Europe is expected to be the second largest market over the forecast time period and closely follow North America in terms of revenue. Asia Pacific is expected to grow rapidly over the forecast time period, owing to the presence of developing economies such, as India and China, the presence of strong healthcare infrastructure, increased affordability, and substantial technological advancements.

Some key players of the global myasthenia gravis market are Novartis Pharmaceuticals Corporation, AbbVie Inc., Biogen Inc., Pfizer, Valeant Pharmaceuticals International, Bristol-Myers Squibb Company, F. Hoffmann Roche La Ltd., GlaxoSmithKline, RPG Life Sciences, and Grifols SA, among others.

Choose License Type

  • zion payment modes


Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed